TABLE 1.
Characteristics | Frequency | Percentage |
Age at melanoma diagnosis (n = 305) | ||
Median, 56 (range = 18–86) years | ||
Sex (n = 305) | ||
Male | 193 | 63.3 |
Female | 112 | 36.7 |
Primary site (n = 305) | ||
Limbs | 82 | 26.9 |
Head and neck | 39 | 12.8 |
Trunk | 134 | 43.9 |
Occult | 35 | 11.5 |
Mucosa | 6 | 2.0 |
Uvea | 9 | 3.0 |
Histology (n = 239) | ||
SSM | 88 | 36.8 |
Nodular | 95 | 39.7 |
Acral | 9 | 3.8 |
Lentigo Maligna | 1 | 0.4 |
Mucosal | 6 | 2.5 |
Uveal | 9 | 3.8 |
Other | 31 | 13.0 |
Breslow depth (n = 239) | ||
≤1 mm | 28 | 11.7 |
>1–2 mm | 48 | 20.1 |
>2–4 mm | 73 | 30.5 |
>4 mm | 90 | 37.7 |
Ulceration (n = 239) | ||
Present | 138 | 57.7 |
Absent | 101 | 42.3 |
Number of mitosis (n = 201) | ||
≤1 | 46 | 22.9 |
>1 | 155 | 77.1 |
Tumor-infiltrating lymphocytes (n = 169) | ||
Brisk | 37 | 21.9 |
Absent or not brisk | 132 | 78.1 |
Lymph node mts (n = 263) | ||
N0 | 133 | 50.6 |
N+ | 130 | 49.4 |
BRAF status (n = 285) | ||
Mutated | 168 | 58.9 |
Wild type | 117 | 41.1 |
NRAS status (n = 59) | ||
Mutated | 21 | 35.6 |
Wild type | 38 | 64.4 |
LDH levels (n = 105) | ||
≤2 × ULN | 82 | 78.1 |
>2 × ULN | 23 | 21.9 |
LDH, lactate dehydrogenase; ULN, upper limit of normal; SSM, superficial spreading melanoma; mts, metastases.